Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2021

01-05-2021 | COVID-19 | Letter to the Editor

Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients

Authors: Bingwen Eugene Fan, Thirugnanam Umapathi, Karen Chua, Yew Woon Chia, Shiun Woei Wong, Glenn Wei Leong Tan, Sadhana Chandrasekar, Ying Hui Lum, Shawn Vasoo, Rinkoo Dalan

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2021

Login to get access

Excerpt

We read with interest the editorial “Anticipating the long-term cardiovascular effects of COVID-19 [1]” which featured COVID-19 end-organ thrombotic complications. COVID-19 associated hypercoagulability [2] and increased thromboembolism in COVID-19 has been well described [3]. While the editorial raised the key question about “potential long-term cardiovascular effects (of COVID-19)”, little is known about the post COVID-19 vascular complications. In response, we would like to highlight a series of catastrophic arterial events observed in post COVID-19 patients (Table 1), echoing the Editor’s concerns of post-infectious vasculopathy.
Table 1
Four cases of post COVID-19 acute arterial thromboses
No
Age
Ethnic group
Sex
Presentation
Arterial events and co-morbidities
Imaging
SARS-CoV total antibody
SARS-CoV PCR
Date of arterial event
Days from positive serology to thrombosis
Treatment
Initial haemostatic assessment
Repeat haemostatic assessment
Current status
1
38
Indian
M
Fall with Acute right sided weakness
Global aphasia NIHSS: 23
Acute left MCA infarct
No comorbidities
MRI brain
Diffuse loss of grey-white differentiation and restricted diffusion involving the left fronto-parieto-temporal lobes and left basal ganglia
Positive × 1
27 May
Not tested
7 July
41 days
1.IV rtPA
2.Endovascular therapy
3. Aspirin
PT 13.5
APTT 26.4
D-dimer 3.20
Fibrinogen 2.7
vWF 260%
Factor VIII NA
Platelets 227
22 July > 3 Aug > 7 Oct
PT 14.3 > 13.5 > 13.3
APTT 28.8 > 31.1 > 27.1
D-dimer 3.39 > 1.22 > 0.46
Fibrinogen 7.5 > 5.6 > 3.3
vWF 272% > 240% > 186%
Factor VIII 208% (7 Oct)
Platelets 583 > 369 > 256
71 days in Rehabilitation
2
39
Indian
M
Acute right sided weakness
Global aphasia
NIHSS: 25
Left MCA and PCA infarct
Pulmonary Embolism
Infrarenal aortic thrombus
Newly diagnosed DM
MRI brain
Large area of restricted diffusion is noted in the left fronto-parieto-temporal lobes, the left occipital and posterior medial temporal lobes
CT pulmonary angiogram
Thrombi seen in the right lower lobe, left upper lobe, left lower lobar, segmental and segmental branches. The main pulmonary arteries have no filling defects seen
CT abdomen/pelvis
Eccentric mural thrombus in the infrarenal aorta
Positive × 2
21 May
14 Aug
Negative × 2
20 Aug
21 Aug
5 Aug
76 days
1.Thrombectomy
2.Craniectomy
3.Low molecular weight heparin with bridging to warfarin
PT 13.7
APTT 26.6
D-dimer 3.55
Fibrinogen 5.8
vWF 226%
Factor VIII 238%
Platelets 301
30 Sept
PT 30.9
APTT 38.4
Fibrinogen 4.7
vWF 153%
Factor VIII 217%
Platelets 256
30 days in Rehabilitation
3
49
Indian
M
Left acute painful lower limb
Left acute ischaemic limb
Infrarenal aortic thrombus
No comorbidities
CT angiography
Occlusion of the left popliteal artery extending to tibioperoneal trunk and into the origins of the ATA, PTA and peroneal arteries. Aetiology is likely an embolus from the distal aorta/left common iliac artery
Positive × 1
3 June
Negative × 3
12 May
21 May
2 Sept
2 Sept
91 days
1.Thrombectomy
2.IV Heparin followed by Rivaroxaban
PT 13.1
APTT 26.7
D-dimer 0.42
Fibrinogen NA
Factor VIII 216%
vWF 161%
Platelets 256
Not assessed yet as thrombotic event was recent
Discharged Home Well
4
38
Indian
M
Chest pain and sudden collapse
ST-Elevation myocardial infarction
No comorbidities
Coronary angiogram
1. Dominance—Right-dominant
2. LM—Free of significant disease
3. LAD—Ostial LAD occluded
4. LCx—Normal
5. Ramus intermedius ( RI)—Normal
6. RCA – Normal
Positive × 1
9 July
Negative × 1
29 May
Negative × 4
24 June
27 Sept
28 Sept
3 Oct
27 Sept
80 days
1.PCI with drug eluting stent to LAD
2. Intraaortic balloon pump
3. Heparin
4. Aspirin
5. Ticagrelor
PT 15.7
APTT 31.8
D-dimer 4.11
Fibrinogen 5.2
vWF 374%
Platelets 156
Not assessed yet as thrombotic event was recent
Admitted to cardiac intensive care unit
NIHSS National Institutes of Health Stroke Scale, MCA middle cerebral artery, PCA posterior cerebral artery, MRI magnetic resonance imaging, IV rTPA intravenous recombinant tissue plasminogen activator, CT computer tomography, DM diabetes mellitus, LM left main, LAD left anterior descending artery, LCx left circumflex artery, RCA right coronary artery, PCI percutaneous coronary intervention, NA not available
Prothrombin Time (PT): 11.7–14.0 s. Activated partial thromboplastin time (aPTT): 27.0–37.0 s. Fibrinogen: 1.8–4.5 g/L. D-Dimer: < 0.5 μg/ml. Platelets: 150–360 × 109/L. Factor VIII: 60–150%. Von Willebrand Factor (vWF): 56–160%
Literature
1.
go back to reference Becker RC (2020a) Anticipating the long-term cardiovascular effects of COVID-19. J Thromb Thrombolysis 50:512–524CrossRef Becker RC (2020a) Anticipating the long-term cardiovascular effects of COVID-19. J Thromb Thrombolysis 50:512–524CrossRef
3.
go back to reference Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147CrossRef Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147CrossRef
4.
go back to reference Varga Z, Flammer AJ, Steiger P et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418CrossRef Varga Z, Flammer AJ, Steiger P et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418CrossRef
6.
go back to reference Goh SSN, Yong EM, Hong QT et al (2020) Acute aortic thrombosis presenting as acute limb ischemia in two young, non-atherosclerotic patients. Br J Surg 107:e565–e566CrossRef Goh SSN, Yong EM, Hong QT et al (2020) Acute aortic thrombosis presenting as acute limb ischemia in two young, non-atherosclerotic patients. Br J Surg 107:e565–e566CrossRef
9.
go back to reference Starling N, Rao S, Cunningham D, Iveson T et al (2009) Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 10:3786–3793CrossRef Starling N, Rao S, Cunningham D, Iveson T et al (2009) Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 10:3786–3793CrossRef
10.
go back to reference Colmenero I, Santonja C, Alonso-Riaño M et al (2020) SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol 183:729–737CrossRef Colmenero I, Santonja C, Alonso-Riaño M et al (2020) SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol 183:729–737CrossRef
11.
go back to reference Goshua G, Pine AB, Meizlish ML et al (2020) Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 7:e575–e582CrossRef Goshua G, Pine AB, Meizlish ML et al (2020) Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 7:e575–e582CrossRef
13.
go back to reference Moreno PR, Narula J (2014) Thinking outside the lumen: fractional flow reserve versus intravascular imaging for major adverse cardiac event prediction. J Am Coll Cardiol 63:1141–1144CrossRef Moreno PR, Narula J (2014) Thinking outside the lumen: fractional flow reserve versus intravascular imaging for major adverse cardiac event prediction. J Am Coll Cardiol 63:1141–1144CrossRef
14.
go back to reference Bharadwaj AS, Vengrenyuk Y, Yoshimura T, Baber U, Hasan C et al (2016) Multimodality intravascular imaging to evaluate sex difference in plaque morphology in stable CAD. J Am Coll Cardiol 9(4):400–407CrossRef Bharadwaj AS, Vengrenyuk Y, Yoshimura T, Baber U, Hasan C et al (2016) Multimodality intravascular imaging to evaluate sex difference in plaque morphology in stable CAD. J Am Coll Cardiol 9(4):400–407CrossRef
15.
go back to reference Shi S, Qin M, Shen B et al (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan China. JAMA Cardiol 5(7):802–810CrossRef Shi S, Qin M, Shen B et al (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan China. JAMA Cardiol 5(7):802–810CrossRef
16.
go back to reference Guagliumi G, Sonzogni A, Pescetelli I, Pellegrini D, Finn AV (2020) Microthrombic and ST-segment elevation myocardial infarction in COVID-10. Circulation 142(8):804–809CrossRef Guagliumi G, Sonzogni A, Pescetelli I, Pellegrini D, Finn AV (2020) Microthrombic and ST-segment elevation myocardial infarction in COVID-10. Circulation 142(8):804–809CrossRef
Metadata
Title
Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients
Authors
Bingwen Eugene Fan
Thirugnanam Umapathi
Karen Chua
Yew Woon Chia
Shiun Woei Wong
Glenn Wei Leong Tan
Sadhana Chandrasekar
Ying Hui Lum
Shawn Vasoo
Rinkoo Dalan
Publication date
01-05-2021
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02332-z

Other articles of this Issue 4/2021

Journal of Thrombosis and Thrombolysis 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine